The reason no distinct difference was apparent between the CD44 serum level in healthy subjects and tumor patients may have been because CD44 variants such as CD44v5, CD44v6 and CD44v10, possibly involved in prostate cancer progression, were not individually evaluated [36,37]. The gene discussed is CD44; the disease is neoplasm.